
CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. Uncertainties about its biological function plagued the early years after its discovery until 1995, when it was confirmed to be an inhibitor of T cell responses. CTLA-4 has since scored in the clinic as a target for antitumor therapy and as a soluble inhibitor of autoimmunity.
From the Archive, Antigens, CD, B7-1 Antigen, Humans, CTLA-4 Antigen, CD8-Positive T-Lymphocytes, Antigens, Differentiation, Immunosuppressive Agents, Cell Proliferation
From the Archive, Antigens, CD, B7-1 Antigen, Humans, CTLA-4 Antigen, CD8-Positive T-Lymphocytes, Antigens, Differentiation, Immunosuppressive Agents, Cell Proliferation
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 17 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
